Equities

Vistagen Therapeutics Inc

VTGN:NAQ

Vistagen Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.00
  • Today's Change0.005 / 0.17%
  • Shares traded68.00
  • 1 Year change-46.43%
  • Beta0.7889
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments1191768
Total Receivables, Net--0.270.34
Total Inventory------
Prepaid expenses1.430.532.41
Other current assets, total0.070.070.12
Total current assets1211871
Property, plant & equipment, net2.262.773.08
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets0.100.100.10
Total assets1242175
LIABILITIES
Accounts payable1.552.472.76
Accrued expenses2.791.271.76
Notes payable/short-term debt00.110
Current portion long-term debt/capital leases--0.000
Other current liabilities, total0.790.711.24
Total current liabilities5.124.575.77
Total long term debt00.010
Total debt00.110
Deferred income tax------
Minority interest------
Other liabilities, total4.244.434.16
Total liabilities9.379.019.93
SHAREHOLDERS EQUITY
Common stock0.030.010.21
Additional paid-in capital474343336
Retained earnings (accumulated deficit)(356)(327)(268)
Treasury stock - common(3.97)(3.97)(3.97)
Unrealized gain (loss)------
Other equity, total------
Total equity1141265
Total liabilities & shareholders' equity1242175
Total common shares outstanding277.316.88
Treasury shares - common primary issue0.000.000.00
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.